D. Boss

发表

Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs

D. Boss, 2009 .

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

A. Ashworth, A. Tutt, J. Carmichael, 2009, The New England journal of medicine.

Application of PET/CT in the development of novel anticancer drugs.

J. Schellens, J. Beijnen, D. Boss, 2008, The oncologist.

Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC

P. Jänne, J. Engelman, J. Schellens, 2008 .

Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152.

J. Schellens, J. Beijnen, E. Voest, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of point-of-care C-reactive protein testing on antibiotic prescription habits in primary care in the Netherlands

D. Boss, A. Demir, R. Musson, 2018, Family practice.

First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers

A. Tutt, J. Carmichael, J. Schellens, 2007 .

AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

J. Carmichael, J. Bono, J. Schellens, 2008 .

Inducing synthetic lethality using PARP inhibitors.

J. Schellens, J. Beijnen, D. Boss, 2010, Current clinical pharmacology.

Clinical experience with aurora kinase inhibitors: a review.

Jos H Beijnen, David S Boss, J. Schellens, 2009, The oncologist.

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Jan Lubinski, Alan Ashworth, Susan Shanley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

J. Schellens, David M. Wilson, E. Voest, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

L. Chirieac, R. Plummer, M. Ranson, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma.

Jos H Beijnen, David S Boss, C. Damen, 2009, Analytical biochemistry.

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

P. Jänne, J. Engelman, J. Schellens, 2011, Clinical Cancer Research.

First-in-human study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer

J. Schellens, D. Camidge, C. Britten, 2007 .

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

J. Wanders, J. Schellens, J. Beijnen, 2012, British Journal of Cancer.

Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2009, Clinical Cancer Research.

Serum β-HCG and CA-125 as Tumor Markers in a Patient with Osteosarcoma: Case Report

D. de Jong, J. Wanders, J. Schellens, 2011 .

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer

W. M. Smit, J. Schellens, H. Rosing, 2015, Investigational New Drugs.

Malondialdehyde in plasma, a biomarker of global oxidative stress during mini-CABG compared to on- and off-pump CABG surgery: a pilot study.

L. Aarts, D. Boss, E. V. van Dongen, 2005, Interactive cardiovascular and thoracic surgery.

Institutional report-Cardiopulmonary bypass Malondialdehyde in plasma , a biomarker of global oxidative stress during mini-CABG compared to on-and off-pump CABG surgery : a pilot study

D. Boss, E. P. Dongen, F. Haas, 2006 .

Serum β-HCG and CA-125 as Tumor Markers in a Patient with Osteosarcoma: Case Report

D. de Jong, J. Wanders, J. Schellens, 2011, Tumori.

Assessment of clinical activity of E7080, a multitargeted kinase inhibitor, in patients with advanced melanoma treated in two phase I trials.

J. Nemunaitis, J. Schellens, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical experience with aurora kinase inhibitors: a review.

J. Schellens, J. Beijnen, D. Boss, 2009, The oncologist.

Application of PET/CT in the development of novel anticancer drugs.

J. Schellens, J. Beijnen, D. Boss, 2008, The oncologist.